Publications and Presentations
Effective SOD1 targeting with vMiXTM, an innovative AAV-based RNA interference platform
Date: Oct 23, 2024
Conference / Journal: ESGCT 2024
Author(s): L. Reilly
Development of an in vitro potency assay for AVB-101, a recombinant AAV9 gene therapy for the treatment of frontotemporal dementia with progranulin mutations
Date: Oct 23, 2024
Conference / Journal: ESGCT 2024
Author(s): R. Lyth
Development of a triplex one-step RT-ddPCR method as a quantitative potency assay for the vMiXTM platform
Date: Oct 23, 2024
Conference / Journal: ESGCT 2024
Author(s): R. Lyth
The vMiX™ platform: Tailored miRNA gene therapy targeting molecular drivers of ALS and FTD
Date: Oct 22, 2024
Conference / Journal: ESGCT 2024
Author(s): A. Ule
Effective knockdown of ATXN2 following intracerebroventricular administration of AVB-205 construct in BAC-ATXN2-Q72 transgenic mice
Date: Oct 22, 2024
Conference / Journal: ESGCT 2024
Author(s): P.M. Coan
Development of HPLC-based methods for the systematic quantification of multiple quality attributes of AAV9 preparations
Date: Oct 22, 2024
Conference / Journal: ESGCT 2024
Author(s): A. Martorana
Pre-Clinical Development of AVB-101, an AAV Gene Therapy Treatment for Frontotemporal Dementia with Progranulin Mutations
Date: Sep 21, 2024
Conference / Journal: ISFTD 2024
Author(s): Youn Bok Lee PhD
ASPIRE-FTD: A Phase 1/2 Clinical Trial to Evaluate AVB-101 in FTD with GRN Mutations: Study Update
Date: Sep 19, 2024
Conference / Journal: ISFTD 2024
Author(s): Jane Chan
ASPIRE-FTD: A Phase 1/2 Clinical Trial to Evaluate AVB-101 in FTD with GRN mutations (FTD-GRN)
Date: Sep 19, 2024
Conference / Journal: ISFTD 2024
Author(s): Jane Chan
Pre-Clinical Development of AVB-101, an AAV Gene Therapy Treatment for Frontotemporal Dementia with Progranulin Mutations
Date: Jul 28, 2024
Conference / Journal: AAIC 2024
Author(s): Youn Bok Lee PhD
vMiX™, an Innovative AAV-Based RNA Interference Platform: First Applications to Treat ALS
Date: May 10, 2024
Conference / Journal: ASGCT 2024
Author(s): Romain Joubert PhD
vMiX™: Towards a “Plug-and-Play” Platform for Gene Silencing Therapy in Neurodegenerative Diseases
Date: May 10, 2024
Conference / Journal: ASGCT 2024
Author(s): Catia Andreassi PhD